Gossamer Bio Option to Acquire Respira Therapeutics
September 25, 2025
Respira Therapeutics, a Samsara BioCapital portfolio company, entered into an agreement granting Gossamer Bio an option to acquire Respira. The transaction is intended to accelerate development of RT234 (vardenafil inhalation powder), a potential PRN therapy for pulmonary hypertension including PAH and PH-ILD, with Gossamer funding specified pre-agreed development activities during the option period.
- Buyers
- Gossamer Bio, Inc.
- Targets
- Respira Therapeutics, Inc.
- Sellers
- Samsara BioCapital
- Platforms
- Respira Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.